Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.34 Billion CNY | -15.34% |
| 2022 | 3.94 Billion CNY | -8.06% |
| 2021 | 4.29 Billion CNY | 9.91% |
| 2020 | 3.9 Billion CNY | 29.91% |
| 2019 | 3 Billion CNY | 16.43% |
| 2018 | 2.58 Billion CNY | 64.57% |
| 2017 | 1.56 Billion CNY | 43.65% |
| 2016 | 1.09 Billion CNY | 64.71% |
| 2015 | 663.26 Million CNY | 23.38% |
| 2014 | 537.57 Million CNY | 22.79% |
| 2013 | 437.79 Million CNY | 12.6% |
| 2012 | 388.79 Million CNY | 23.76% |
| 2011 | 314.15 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.2 Billion CNY | -2.96% |
| 2024 Q3 | 3.13 Billion CNY | -2.3% |
| 2024 Q1 | 3.3 Billion CNY | -1.07% |
| 2023 Q1 | 3.73 Billion CNY | -5.3% |
| 2023 FY | 3.34 Billion CNY | -15.34% |
| 2023 Q4 | 3.34 Billion CNY | -10.95% |
| 2023 Q3 | 3.75 Billion CNY | 0.73% |
| 2023 Q2 | 3.72 Billion CNY | -0.34% |
| 2022 Q4 | 3.94 Billion CNY | -5.57% |
| 2022 Q3 | 4.18 Billion CNY | -2.1% |
| 2022 Q1 | 4.48 Billion CNY | 4.56% |
| 2022 Q2 | 4.27 Billion CNY | -4.89% |
| 2022 FY | 3.94 Billion CNY | -8.06% |
| 2021 Q2 | 3.96 Billion CNY | -1.66% |
| 2021 Q3 | 4.12 Billion CNY | 4.2% |
| 2021 Q4 | 4.29 Billion CNY | 4.03% |
| 2021 Q1 | 4.02 Billion CNY | 3.12% |
| 2021 FY | 4.29 Billion CNY | 9.91% |
| 2020 Q1 | 3.2 Billion CNY | 6.71% |
| 2020 FY | 3.9 Billion CNY | 29.91% |
| 2020 Q3 | 3.68 Billion CNY | 20.38% |
| 2020 Q2 | 3.05 Billion CNY | -4.65% |
| 2020 Q4 | 3.9 Billion CNY | 6.06% |
| 2019 FY | 3 Billion CNY | 16.43% |
| 2019 Q4 | 3 Billion CNY | -0.63% |
| 2019 Q3 | 3.02 Billion CNY | -0.06% |
| 2019 Q2 | 3.02 Billion CNY | 8.24% |
| 2019 Q1 | 2.79 Billion CNY | 8.3% |
| 2018 Q2 | 2.43 Billion CNY | 46.95% |
| 2018 Q1 | 1.65 Billion CNY | 5.58% |
| 2018 Q3 | 2.42 Billion CNY | -0.53% |
| 2018 FY | 2.58 Billion CNY | 64.57% |
| 2018 Q4 | 2.58 Billion CNY | 6.64% |
| 2017 Q3 | 1.45 Billion CNY | 13.68% |
| 2017 FY | 1.56 Billion CNY | 43.65% |
| 2017 Q4 | 1.56 Billion CNY | 8.04% |
| 2017 Q2 | 1.27 Billion CNY | 16.46% |
| 2017 Q1 | 1.09 Billion CNY | 0.43% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 1.09 Billion CNY | 64.71% |
| 2016 Q4 | 1.09 Billion CNY | 41.12% |
| 2016 Q2 | 727.64 Million CNY | 0.0% |
| 2016 Q3 | 774.16 Million CNY | 6.39% |
| 2015 Q4 | 663.26 Million CNY | 0.0% |
| 2015 FY | 663.26 Million CNY | 23.38% |
| 2014 FY | 537.57 Million CNY | 22.79% |
| 2013 FY | 437.79 Million CNY | 12.6% |
| 2012 FY | 388.79 Million CNY | 23.76% |
| 2011 FY | 314.15 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 14.3 Billion CNY | 76.647% |
| Joinn Laboratories(China)Co.,Ltd. | 10.02 Billion CNY | 66.673% |
| WuXi AppTec Co., Ltd. | 74.26 Billion CNY | 95.5% |
| Autobio Diagnostics Co., Ltd. | 11.55 Billion CNY | 71.077% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 11.76 Billion CNY | 71.602% |
| Chemclin Diagnostics Co., Ltd. | 1.82 Billion CNY | -83.558% |